<SEC-DOCUMENT>0001144204-13-036784.txt : 20130627
<SEC-HEADER>0001144204-13-036784.hdr.sgml : 20130627
<ACCEPTANCE-DATETIME>20130627080852
ACCESSION NUMBER:		0001144204-13-036784
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130627
FILED AS OF DATE:		20130627
DATE AS OF CHANGE:		20130627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAMADA LTD
		CENTRAL INDEX KEY:			0001567529
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35948
		FILM NUMBER:		13936001

	BUSINESS ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
		BUSINESS PHONE:		97289406472

	MAIL ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v348790_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of June, 2013_</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number 001-35948</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Kamada Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>7 Sapir St.</B><BR>
<B>Kiryat Weizmann Science Park</B><BR>
<B>P.O Box 4081</B><BR>
<B>Ness Ziona 74140</B><BR>
<B>Israel</B><BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Wingdings 2">T </FONT>
Form 40-F <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant by furnishing
the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT>
&nbsp;&nbsp;No <FONT STYLE="font-family: Wingdings 2">T</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attached hereto and incorporated herein by reference is a press
release of the Company, dated June 27<SUP>th</SUP>, 2013 entitled: <B>&quot;Ka<FONT STYLE="color: black">mada Announces Successful
GMP Manufacturing Audit by Israel's Ministry of Health</FONT>.&quot;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%; text-align: left; vertical-align: middle"><FONT STYLE="font-size: 20pt; color: #333399"><B>News Release</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>KAMADA ANNOUNCES SUCCESSFUL GMP MANUFACTURING
AUDIT BY ISRAEL'S MINISTRY OF HEALTH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NESS ZIONA, Israel (June 27, 2013) &ndash;
Kamada Ltd. (Nasdaq and TASE: KMDA) </B>today announced that Israeli Ministry of Health (IMOH) has completed a successful Good
Manufacturing Practice (GMP) audit of the Company's manufacturing facility in Beit Kama, Israel. The audit was performed as part
of the Ministry of Health's routine evaluation of the company's manufacturing process for its plasma-derived protein therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit concludes that Kamada complies
with the GMP requirements of the IMOH. As the IMOH is also a member of the Pharmaceutical Inspection Convention and Pharmaceutical
Inspection Co-operation Scheme (PIC/S), this audit is also issued under the provisions of the Conformity Assessment and Acceptance
of Industrial Products (CAA) Agreement between the European Union and Israel. The audit concludes that Kamada complies with GMP
requirements for the manufacture of medicinal products, the importation of medicinal products and the manufacture of active substances
using biological processes. This compliance status is good for three years from the time of the audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Kamada takes great pride in maintaining
the highest quality manufacturing processes as it is a core competency of the Company and a cornerstone of our commercial success.
This positive audit underscores the viability, quality and high standards Kamada upholds in the manufacture of our plasma-derived
therapeutic proteins both for commercial use and for products under development in compliance with international standards,&rdquo;
said David Tsur, the Chief Executive Officer of Kamada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Kamada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Kamada Ltd. is focused on plasma-derived
protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline.
The company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma
to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT has known
and newly discovered therapeutic roles given its immuno-modulatory, anti-inflammatory, tissue-protective and antimicrobial properties.
The Company&rsquo;s flagship product is Glassia&reg;, the first and only liquid, ready-to-use, intravenous plasma-derived AAT
product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership
with Baxter International. Kamada has nine other injectable pharmaceutical products that are marketed through distributors in
more than 15 countries, including Israel, Russia, Brazil and other countries in Latin America, India, Eastern Europe and Asia.
Kamada has five plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT
deficiency that is in pivotal Phase II/III clinical trials in Europe and Canada and will be entering Phase II clinical trials
in the U.S. In addition, Kamada leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing
10 complementary products in Israel that are manufactured by third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Note Regarding Forward-Looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release contains forward-looking statements
that involve risks, uncertainties and assumptions, such as statements regarding the EMA and U.S. FDA marketing authorization of
our Inhaled AAT for AATD, timing of clinical trials. Actual results and the timing of events could differ materially from those
anticipated in these forward-looking statements as a result of several factors including, but not limited to, delays or denial
in the U.S. FDA or the EMA approval process, additional competition in the AATD market, further regulatory delays. The forward-looking
statements made herein speak only as of the date of this release and the Company undertakes no obligation to update publicly such
forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gil Efron</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CFO<BR>
<U>ir@kamada.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anne Marie Fields</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LHA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">212-838-3777</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>afields@lhai.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 64%; padding-right: 0; padding-left: 0; text-align: left; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;Date: June 27<SUP>th</SUP>, 2013</P></TD>
    <TD STYLE="width: 36%; padding-right: 0; padding-left: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>KAMADA LTD.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">By: &nbsp;/s/ Gil Efron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">Gil Efron</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!7`3X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W*BBB@`HH
MI&944LQ"J.I)H`6BN8U3QMI]DQCMS]HD']WI6!+XVU.X;,*^4OLN:Z882K-7
MM8Y*F-HTW:]_0]&HKSN/Q3K#=9B?^`5?M_%=Y'CSE$GKVJG@JB[&:S&BWK<[
M6BL>P\16EX0C'RI/1NE;`.1D=*YIPE!VDCLIU(5%>+N%%%%26%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`17-Q%:6[SSN$C099C7DWB3QC<:Q</!:LT5H#@8/+5?^(WB-I9QI
M-L^$09E(/4^E<)!VKV<#A$H^TGOT/$QV,<I>R@]%N:$5=?X3U)X[N.S9(S$Q
MR2PKD(JZCPO;1O/-=3KF*!,D>]=.(2=-W..@Y*JN4Z.>\%AHYDA6(N9BO('3
M)KG&<NQ8]3S6]:36D.A1W4MF)S)*0%^IK2:RTZ>S7S[=;623A`#S7%&HJ=[K
MJ==2C*M:TEML<<"0<CK70:+X@>V=8+EBT1.`Q_AK&O+9K2ZDA;JIX/J*@KHG
M"-2-F<=.I.C.ZW/4E974,I!4\@BHKM;AK9A:LBS?PE^E<_X7U,NILY6Y'*9_
ME735XU2#I3LSZ*C55:GS(X"Y\4:Y:ZN--:.$S%@H()P<UVE@M\MMB^:,S?['
M05Y_J_\`R4.W_P"NB5UNNZRZS?V;IXWWDIVY'1!ZFNRO334%!)75V<.&JN+J
M2G)NSLC-NO$.M0ZP=/MH+>Y8\[E)^4>]='IPO_*+7YB\PG($><"H-%T:+2K<
M\F2XDYDD;J36I7-6G!^[!?/N=="G47O5)/T[#)I!#!)(>B*37&^&_%-QJ.O3
MVURP\ML^6H['-;GB:Z,.EF!#^]N&$2_C7"ZK9MX<\16<\>0K`-_C71A:49P:
MEN]OD<N-KSIU(RCM&U_F>IU5OUO6MS]A:-9?^FG2IH)5GMXY4.5=00:DKA3Y
M6>BUS(X.S\8W\>N)8W\<:J7V,0>GO7>`@@$=#TKRCQ!93275[J2CB.8+Q_.N
M[\*ZL-4T:-F;,L?R/7?BZ,>15(+U/-P.(G[25*H[]O0W*Y[Q5X@.AVB>2`T[
MG@'TKH&8*I9C@#DFO,O$XEU:*YU09\F*01QCL1W-8X2E&=1<VQOCJTJ=)\FY
MU/AS4-7U:)+N?R5MR<;1G<:Z6N?\%_\`(MP?4UT%9XBWM&DK6-<+=T8MN[:.
M?\6ZS-H^E[[?'G.=H)[>]3^&-4;5=&CFE;=,#AZS=7M5U[6I;/K';PM_WT1Q
M6/X'O6L=5N=,E.`QR,^HKI5&+P[M\2U^1R.O..*5W[KT^9Z'7*^)-4UC14:Z
M3R'MRV%'.1]:ZJN5\??\B^?]\?SK#"I.JHM73.G&-JC*479H32+_`,0:KIZW
MT)M`A)`1B<\4ESXBUC2VW:AIH,/=XCFK/@?_`)%>#_>:N@EB2:-HY%#(PP01
M5U)PC5<7%63,Z5.<Z,9*;3:*.E:U9:Q"'MI,MW0]16C7F&JQ/X3\3I-:G;`Y
M#;>V#U%>E6TZW-M',GW74,*G$45"TX?"RL+B)5'*$U[T=ROJ]Z=/TJXNE`+1
MKD`]S6!X,U^XU<7$=T^Z4'<OL/2KGB0_:Y;/3%/,S[G_`-VN2LA_PC7C0P-D
M0%]OU%;4:4949+[3U7R,,17G#$1E?W5H_5GIM%`.1FBN`],****`"JVH7(L]
M/N+@G_5H6JS6!XTF,/A:Z9>IP*NG'FFH]R*LN6#EV/$[VY:\O9[AB29'+<TL
M':JXJQ!VKZJUE8^23N[LT(J[6"WDM/#,-O"A-U>L3@#DJ*Y/2[9KN_@@49W,
M,CVKTO7+V/1+*W:WC#R[/+63J$Q7GXF;YHP6YWX:FG&4Y.R10@E.F>'+5Y(P
MSQS?=/K5&&ZGU#5H9)&+,7X'I5^"[B7PO#-=Q>=OEY'OFK&EZA92SF*WMA%(
M4.QCUS7/=Q4GRZZZFK2E*$>:RLM#*UT@ZM+@],"LVI;G?]ID\PY?<<U%75!6
MBD<-27--LL6$YMKZ&53]UA7I,;!XU8=",UY>#@@^E>CZ8_F:9;OZI7#CH[2/
M3RN;O*)YSXA69_'"K`VV8L@0^AJ70]9ET+7IX=30%I7(>1A\P_'TI=7_`.2A
MV_\`UT2NI\5>&DUF%I8@%NDR0?[WM6\JD%&%.ILT80HU)3J5:3]Z,MNYT$<B
M2QK(C!D89!'>G5YWX5\1RZ==?V5J&53=A6?^$UW\]PD%J]PS#8B[LYKSJ]"5
M*?*_D>KA\3&M#F73?R.3UO5;=?%%O'.':&U&X[!GYNU9WB_5;'6-/3[/',)H
MVSEHR.*W/"MNMU#<ZE*@8W,A*EAGC-;ES8P3VLL1A3YE(^[71[6%*I%6UCY_
M><OL:E>E)W5I:[?<8G@C4/MFA)$Q^>$[,>U=+7FOA.Y;2?$]QI\APKL5Y[5Z
M4Q"*6;@`<FLL93Y*KML]3;`5>>BD]UH_D<KI%JNI6.KV\HR'D(^E<UX7O6T+
MQ'+93G:CML.>WI75^#V#PWT@8$M.>G:L'QYI1MKJ'5(!C<<-CU'>NJG).K*C
M+9_F<56#5&&(AO'\KG3^);UX+$6L!_TBZ/EH/8]ZRO$MBNG>"UME'W67<?4]
MZC\+R3Z]?1ZC<CY+9`B`]V[FM#QS_P`BX_\`OBLH+V=6%+SU-YR]K1G6Z-67
MH'@B3?X=C7'W3BN@N)UMK>29B`$4MS[5SG@0@Z!QV>I/&%T4T^.R0_O+IP@Q
MZ9K*I#GQ+CYFU&IR813\C*T#Q#9VWVFXN4F\VX<M\J$\9XKGM2OH8?%,>H6:
MNL98'#KBO3K/3X;2SA@\I#Y:A<XKGO'&EI-HOGQ1JKPMDD#M711KTW6VWTW.
M7$8:JJ&K^'78ZB"59[>.53D.H.:YGQ]_R+Y_WQ_.I/!&I?;M#6%C\\!V<^E1
M^/O^1?/^^/YUC2@Z>)47T9TUJBJX-S75$_@?_D5X/]YJZ.N<\#'/AB$#J&-=
M!--';Q-)*ZHBC))-98C^-+U-L*[8>#\D<%\1]FZV_O\`?Z5UOAX,-!M-V?\`
M5CK]*XB\\WQAXF46R'[+$0"Y'&!7;ZG<1Z1H4C`[0D>Q/KVKIKJU*G1ZG'AF
MG6J8C[/^1S2:Y;+XJN;NY$K1Q+Y<>Q=P'K6/XQU"UU&XAO+1)0Z``ED(KM?#
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M0UYTXN:E473;Y'HQDH2C2>S6OS_I&HW_`")MMGKYM4K.8V]U%*.JD5O:[9"P
M\/10_P#3;/YFN:'04J+4XM]&V9XE.G4BNJ2-37(!'>B91^[F4.#[UF5MR'[=
MX>1NLMLQ!^AK$JJ3?+9]#.NES<RV>HH&2!ZUZ#;PS_V)#%;N(Y=@PQ[5P^G6
MS7=_#$O=N:](1=J*H'08KDQL[<J._+*=^:7R.,F\%W4]_P#;7O\`]_NW!L=*
MZJPBN88-EU*)7'\0JUB@\=:Y*E>=1)2/1I8:G2;E'J<WK_A&WU>=;B)_)F'4
M@=:KOX9U.2P^Q-J9,.,8QVKK*175B0K`D=<&G'$U%%*^Q,L)1<G*VK,'1=&O
MM)1(!=J]NI^Z16U<K*]NZPL$D(^5CVJ6@$$D9Y':LYU'.7,]S6%*,(\D=CBI
M?!-S-?M>M?8G+;MP'>M2?2-8GM?(;4L9&&('45T-%:O$U)6OT\C&.#I1O:^O
MFSEM(\-7VCNWD7H*.<NI'6MO5-.35--DM),98<'T-7=R[MNX;O3-+43K3E+G
M>Y<*%.$'!;&=HFE)H^FQVJD$CEB.YK*UCP]?ZP&BEO@(-VX(!7348S1&M.,^
M?J.6'A*"IO8Y72O#6H:.K);7X\MCDJ1WIE[X6U"_O$N9M0R\9R@`X%=8S*@R
MY"CWXI:OZS4YN;KZ&?U.ER\FMO4JV,5U%$5NIA*_J!536]-NM3MS;PSB.)UP
MX(ZUJT5DIM2YEN;2IJ4.1['(:5X1O-(G\RVO]H.-PQU%6M9\/7VL@QRW@$.<
MA0*Z6BM7B:CESO<Q6#I*'LUMZG):?X7U+2T,=KJ91#_#BK1\,37F#J.I33`?
MP*``:Z.BD\34;OU]!QPE)+EMIVNRK8Z=:Z="(K6(1K[=ZQ-;\/7NLL5>]VP`
MY"`5TM%1"K.,N9;FDZ$)PY&M#+TFQOK%5BN+A98E7"\<U9U"&YGMREM*(V/!
M)':K=%)S;ES#5-*/(MCBK?P5=6E[]KAO]DV<Y`KK[5)H[=5G??(.K>M2AE+%
M0P+#J,TM55K3J?&11P].C?D"BBBLC<****`/-?B-X<8N-7MDR",2@#]:X;3$
MCEO(5D<+&6&YCV%?0$T4<\312J&1A@@]Z\Q\1^#)]+NC?:;'YEOG<4QDK7KX
M/%IQ]E-Z]#QL;@VI^U@M.IF:[?QWVI_N3F&)0B?2J]M(8Y5=3AE.16M;>+&C
M0)+IELSC@DJ!5R/Q6K?\PNV'X"NA.<5RJ'XG)-4Y2YG/7T-36M8M]1T2V1'S
M*""RU@@\"M2/Q*K?\PZ`?A5@>(5Q_P`>$/Y5C!3IKE4?Q+K.%67-*?X,K:1=
M1PO-%,V(Y4P3[UG,`KL`<@'`-:TNMO.ICCLXE+<<+FK^C>'G=Q<WB;5SD(>]
M#J*G><]!*DZMJ=-WMU+GAC3#;PFZE7#N/E!["MF_!-A/AF4A"05."*G`"@`#
M`'2H+U)9;.6.$*7=2HW'`KRY5'.IS,]R%)4J7)$YK3]6"Z`ZR&\>;#?O-I/Z
MT^PN4_L_33=37#22S?*VX]>>M:5A8WEMH;V<BQ^;@A<-P<U132=12SLHF2+_
M`$67S20_7KQ73S0;?J<BA42C?73MYHMR>(H8W`\IVC,GE!@.]9>GZK]AOK]G
MCD=#-R<?=S5.+SHI9+I4CE83Y6-F((_"M5-)U`PWAV1!KAPZC=TI\E."L^I*
MJ5:C373R+FOZB]O96ZP,5:YD5`P[`]ZKZG8RZ?IPOK6YE\Z'!;<V0XJ]?:5_
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M,>2,X]"Y>TG3E?773[S`N9;D6USO>=K:.X'DL^=QX_E70V^NQ.DJO%(CP@97
M;R:=J]E<WMI#'`L897#-DX%4KG2]2FEN7C\I#(JJIW>E5S0J17-I_2)4:E*3
MY=?Z98/B*&.UN)I8G4PD!EQSS3/^$FB$<3M;3+YK;5!0\U1.@ZB+>XC'EGSL
M=7SC%7KO3KZX73BJQ!K9@S#=UP*3C13_`.#Y`IXAK_@>?^0T>*8"&_<2CRY/
M+D)4X4U:O-<AL[A8VC<J7$9?'`)XK,DT;4I(;U"(0;FX$Q^;IC''Z4E]HFI7
MLQD+1C$BR*-W'!SBGR4;[_B'M,0D]-?3U-:75P)66&%Y41@KLHZ5`/$EJT_E
MI\P+;00><_2HK73M3L[B58Y8S!,<L2>5/>F6&BW=E.T9$+0%BPD(^;FIY:23
MU*YZ[:LOP+`\10&".7RVPTGEGCH<U#+KOG?;8GMY5BB4@NHY%56T&_'[I#$8
MEG\T$MR1FK;Z;?\`^G1J(C'<I@9;H:KEHK8GFKO?\BQ%JL4=K`D"/,YCW;>I
MQ[TVY\016T*RM!(!QORN-N3BJ<.CZE:2V]Q;O&)5C\N1">/K4>I:%J5^T@:9
M&#XP=V,8]J2A2<M7H-SKJ.BU+2W4=GK>HSLQ\L0(WXYK2T[4!?H[!"H7&#V.
M:RAIFHF>9V2$B6)8SEO2K6@Z;/IQNC-M592I2-6R%QUJ:B@XMWUT*I.HII6T
MU-BBBBN8[`H-%%`"4Z0"6/;QC'((HHH`Y?5?"-K?,751'(?XEKGY?!EY"Q,<
MJ%?<\T45T4\55AHF<M7"4:FK6HL?AN]7J8_SJ_!X9N6QO=0/8T45I+%U;;F4
M,!1OL;NGZ#%:D-@,WJ:VP=B;3S117+*4I.[9V0A&"M%6&9HS114EAFC-%%`#
M/)B!SY29]=M/S110%@S2.B2+M=%8>C#-%%`"J`JA5``'0"C-%%`!FC-%%`#4
MC2,L40`L<D@=:=FBB@`S1FBB@`S1FBB@`S1FBB@`S1FBB@`S1FBB@`S1FBB@
,`S2BBB@!:***`/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
